SCHEMBL5859947

SCHEMBL5859947

CCOC(=O)c1c(Cc2ccccc2)c2ccccc2[nH]c1=O

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
LMNA P02545 3/20 0.57
TSHR P16473 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.55
HSD17B10 Q99714 1/20 0.55
KDM4E B2RXH2 5/20 0.54
CSF1R P07333 1/20 0.53
HCRTR1 O43613 1/20 0.51
MAPT P10636 1/20 0.51
RAB9A P51151 1/20 0.51
HTR6 P50406 1/20 0.51
PDE3B Q13370 1/20 0.50
PDE3A Q14432 1/20 0.50
MAP3K5 Q99683 1/20 0.50
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11288880 0.86 ALDH1A1 (0.60) ALDH1A1MEN1KMT2ALMNATSHR
SCHEMBL14404807 0.85 ALDH1A1 (0.59) ALDH1A1MEN1KMT2ALMNATSHR
SCHEMBL7671532 0.83 HTR6 (0.68) ALDH1A1TSHRHSD17B10KDM4EMAPT
SCHEMBL1058188 0.83 KDM5A (0.68) ALDH1A1MEN1KMT2ALMNATSHR
SCHEMBL29400098 0.83 KDM4E (0.64) ALDH1A1MEN1KMT2ATSHRKDM4E
SCHEMBL1934130 0.83 KDM4E (0.64) ALDH1A1MEN1KMT2ATSHRKDM4E
SCHEMBL7242790 0.81 ALDH1A1 (0.64) ALDH1A1MEN1KMT2ALMNATSHR
SCHEMBL7818629 0.80 CSF1R (0.74) ALDH1A1MEN1KMT2ALMNATSHR
SCHEMBL1061379 0.79 KDM4E (0.64) ALDH1A1MEN1KMT2ALMNATSHR
SCHEMBL11307581 0.79 KDM4E (0.72) ALDH1A1MEN1KMT2ALMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135478-B2 Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2006-11-14 US disclosed
US-7012079-B1 Optically pure camptothecin analogues SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2006-03-14 US disclosed
US-20050038064-A1 Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) 2005-02-17 US disclosed
US-6815546-B2 ANTICANCER AGENTS SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-11-09 US disclosed
US-20030004150-A1 New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them IPSEN PHARMA S.A.S. (FR) 2003-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004150-A1 New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them TOP1, TOP2A, TYMP ALDH1A1 795/4885MEN1 62/4885KMT2A 4064/4885
US-20050038064-A1 Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione MCL1, BRCA1, API5 ALDH1A1 284/4885MEN1 578/4885KMT2A 1052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.